International Nonproprietary Names for Pharmaceutical Substances

In accordance with article 3 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances,[1] notice is hereby given that the following names are under consideration by the World Health Organization as Proposed International Nonproprietary Names.

Comments on, or formal objections to, the proposed names may be forwarded by any person to the Pharmaceuticals unit of the World Health Organization within four months of the date of their publication in *WHO Drug Information,* e.g., for List 64 Prop. INN not later than 31 August 1991.

The inclusion of a name in the lists of proposed international nonproprietary names does not imply any recommendation for the use of the substance in medicine or pharmacy.

Action and Use

The statements in italics indicating the action and use are based largely on information supplied by the manufacturer. The information is meant to provide an indication of the potential use of new substances at the time they are accorded proposed INNs. WHO is not in a position either to uphold these statements or to comment on the efficacy of the action claimed. Because of their provisional nature these descriptors will be neither revised nor included in the Cumulative Lists of INNs.

Proposed International Nonproprietary Names (Prop. INN): List 64[2]

Comprehensive information on the INN programme can be found in: WHO Technical Report Series, No. 581, 1975 (*Nonproprietary Names for Pharmaceutical Substances* Twentieth Report of the WHO Expert Committee), ISBN 92 4 120581 4 (price Sw. fr. 6.–); an account of this publication will be found in Annex 2 of the present List All names from Lists 1–58 of Proposed International Nonproprietary Names, together with a molecular formula index, will be found in *International Nonproprietary Names (INN) for Pharmaceutical Substances. Cumulative List No. 7,* 1988, World Health Organization, Geneva (ISBN 92 4 0560149) (price Sw fr 65.–) This publication consists, in the main, of a computer printout which groups together all the proposed and recommended international nonproprietary names (INN)—in Latin, English, French, Russian, and Spanish—published up to March 1988 The printout also indicates in which of the 58 individual lists of proposed names and 27 lists of recommended names each INN was originally published, and gives references to national nonproprietary names, pharmacopoeia monographs, and other sources. In addition, the list contains molecular formulae and Chemical Abstracts Service registry numbers For easy reference, national nonproprietary names that differ from INN, molecular formulae, and Chemical Abstracts Service registry numbers are indexed in a series of annexes A final annex describes the procedure for selecting recommended INN and outlines the general principles to be followed in devising these names. All the textual material published in this volume appears in both English and French

These publications may be obtained, direct or through booksellers, from the sales agents listed on the back cover of *WHO Drug Information.* Orders from countries where sales agents have not yet been appointed may be addressed to World Health Organization, Distribution and Sales Service 1211 Geneva 27, Switzerland.

[1] Text adopted by the Executive Board of WHO in resolution EB15.R7 (*Off. Rec. Wld Hlth Org.,* 1955, **60**, 3) and amended by the Board in resolution EB43.R9 (*Off Rec. Wld. Hlth Org.,* 1969, **173**, 10).

[2] Other lists of proposed and recommended international nonproprietary names can be found in *Cumulative List No. 7,* 1988.

Proposed International Nonproprietary Name (Latin, English)	*Chemical Name or Description, Molecular and Graphic Formulae* *Chemical Abstracts Service (CAS) registry number* *Action and use*
abanoquilum abanoquil	4-amino-2-(3,4-dihydro-6,7-dimethoxy-2(1*H*)-isoquinolyl)-6,7-dimethoxyquinoline $C_{22}H_{25}N_3O_4$ 90402-40-7 *α_1-adrenoreceptor antagonist* 
acadesinum acadesine	5-amino-1-β-D-ribofuranosylimidazole-4-carboxamide $C_9H_{14}N_4O_5$ 2627-69-2 *cardiac stimulant* 
acidum gadobenicum gadobenic acid	dihydrogen (±)-[4-carboxy-5,8,11-tris(carboxymethyl)-1-phenyl-2-oxa-5,8,11-triazatridecan-13-oato(5-)]gadolinate(2-) $C_{22}H_{28}GdN_3O_{11}$ 113662-23-0 *paramagnetic contrast medium* 
adapalenum adapalene	6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid $C_{28}H_{28}O_3$ 106685-40-9 *antiacne agent* 
adozelesinum adozelesin	(7b*R*,8a*S*)-*N*-[2-[(4,5,8,8a-tetrahydro-7-methyl-4-oxocyclopropa[*c*]pyrrolo-[3,2-*e*]indol-2(1*H*)-yl)carbonyl]indol-5-yl]-2-benzofurancarboxamide $C_{30}H_{22}N_4O_4$ 110314-48-2 *antineoplastic* 

Proposed International Nonproprietary Name (Latin, English)	*Chemical Name or Description, Molecular and Graphic Formulae* *Chemical Abstracts Service (CAS) registry number* *Action and use*
alentemolum alentemol	(+)-2-(dipropylamino)-2,3-dihydrophenalen-5-ol $C_{19}H_{25}NO$ 112891-97-1 *antipsychotic*
	
...okalantum ...mokalant	(±)-*p*-[3-[ethyl[3-(propylsulfinyl)propyl]amino]-2-hydroxypropoxy]benzonitrile $C_{18}H_{28}N_2O_3S$ 123955-10-2 *antidysrhytmic*
	
ameltolidum ameltolide	4-amino-2′,6′-benzoxylidide $C_{15}H_{16}N_2O$ 787-93-9 *anticonvulsant*
	
angiotensinum II angiotensin II	5-L-isoleucineangiotensin II The source of the material should be indicated. $C_{50}H_{71}N_{13}O_{12}$ 4474-91-3 *vasoconstrictor*
	
aprikalimum aprikalim	(–)-(1*R**,2*R**)-tetrahydro-*N*-methyl-2-(3-pyridyl)thio-2*H*-thiopyran-2-carboxamide 1-oxide $C_{12}H_{16}N_2OS_2$ 92569-65-8 *potassium channel activator*
	

Proposed International Nonproprietary Name (Latin, English)	*Chemical Name or Description, Molecular and Graphic Formulae* *Chemical Abstracts Service (CAS) registry number* *Action and use*
aprosulatum natricum aprosulate sodium	*N,N'*-trimethylenebis[lactobionamide] hexadecakis(sodium sulfate) (ester) $C_{27}H_{34}N_2Na_{16}O_{70}S_{16}$ 123072-45-7 *anticoagulant* 
arbutaminum arbutamine	(*R*)-3,4-dihydroxy-α-[[[4-(*p*-hydroxyphenyl)butyl]amino]methyl]benzyl alcohol $C_{18}H_{23}NO_4$ 128470-16-6 *cardiac stimulant* 
avizafonum avizafone	2'-benzoyl-4'-chloro-2-[(*S*)-2,6-diaminohexanamido]-*N*-methylacetanilide $C_{22}H_{27}ClN_4O_3$ 65617-86-9 *anxiolytic, anticonvulsant* 
barnidipinum barnidipine	(+)-(3'*S*,4*S*)-1-benzyl-3-pyrrolidinyl methyl 1,4-dihydro-2,6-dimethyl-4-(*m*-nitrophenyl)-3,5-pyridinedicarboxylate $C_{27}H_{29}N_3O_6$ 104713-75-9 *calcium antagonist* 

Proposed International Nonproprietary Name (Latin, English)	*Chemical Name or Description, Molecular and Graphic Formulae* *Chemical Abstracts Service (CAS) registry number* *Action and use*
batelapinum batelapine	2-methyl-5-(4-methyl-1-piperazinyl)-11*H*-*s*-triazolo[1,5-*c*][1,3]benzodiazepine $C_{16}H_{20}N_6$ 95634-82-5 *antipsychotic*
	
bemesetronum bemesetron	*endo*-8-methyl-8-azabicyclo[3.2.1]oct-3-yl 3,5-dichlorobenzoate $C_{15}H_{17}Cl_2NO_2$ 40796-97-2 *serotonin antagonist*
	
bertosamilum bertosamil	3′-isobutyl-7′-isopropylspiro[cyclohexane-1,9′-[3,7]diazabicyclo[3.3.1]nonane] $C_{19}H_{36}N_2$ 126825-36-3 *anti-ischaemic*
	
betamipronum betamipron	*N*-benzoyl-*β*-alanine $C_{10}H_{11}NO_3$ 3440-28-6
	
bimakalimum bimakalim	2,2-dimethyl-4-(2-oxo-1(2*H*)-pyridyl)-2*H*-1-benzopyran-6-carbonitrile $C_{17}H_{14}N_2O_2$ 117545-11-6 *potassium channel activator*
	

Proposed International Nonproprietary Name (Latin, English)	*Chemical Name or Description, Molecular and Graphic Formulae* *Chemical Abstracts Service (CAS) registry number* *Action and use*
bindaritum bindarit	2-[(1-benzyl-1*H*-indazol-3-yl)methoxy]-2-methylpropionic acid $C_{19}H_{20}N_2O_3$ 130641-38-2 *antirheumatic*



brinazaronum brinazarone	*p*-[3-(*tert*-butylamino)propoxy]phenyl 2-isopropyl-3-indolizinyl ketone $C_{25}H_{32}N_2O_2$ 89622-90-2 *calcium antagonist*



carperitidum carperitide	L-seryl-L-leucyl-L-arginyl-L-arginyl-L-seryl-L-seryl-L-cysteinyl-L-phenylalanylglycylglycyl-L-arginyl-L-methionyl-L-aspartyl-L-arginyl-L-isoleucylglycyl-L-alanyl-L-glutaminyl-L-serylglycyl-L-leucylglycyl-L-cysteinyl-L-asparaginyl-L-seryl-L-phenylalanyl-L-arginyl-L-tyrosine cyclic(7→23)-disulfide $C_{127}H_{203}N_{45}O_{39}S_3$ 89213-87-6 *cardiac stimulant*



cefclidinum cefclidin	(+)-1-[[(6*R*,7*R*)-7-[2-(5-amino-1,2,4-thiadiazol-3-yl)glyoxylamido]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-4-carbamoylquinuclidinium hydroxide, inner salt, 7^2-(*Z*)-(*O*-methyloxime) $C_{21}H_{26}N_8O_6S_2$ 105239-91-6 *antibiotic*



Proposed International Nonproprietary Name (Latin, English)	*Chemical Name or Description, Molecular and Graphic Formulae* *Chemical Abstracts Service (CAS) registry number* *Action and use*
cefdaloximum cefdaloxime	(+)-(6*R*,7*R*)-7-[2-(2-amino-4-thiazolyl)glyoxylamido]-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate, 7^2-(*Z*)-*oxime* $C_{14}H_{15}N_5O_6S_2$ *antibiotic* 
cilonaprilum cilonapril	1-[(2*S*)-6-amino-2-hydroxyhexanoyl]-L-proline, hydrogen (4-phenylbutyl)phosphonate (ester) $C_{21}H_{33}N_2O_6P$ 111223-26-8 *angiotensin converting enzyme inhibitor* 
cetrorelixum cetrorelix	*N*-acetyl-3-(2-naphthyl)-D-alanyl-*p*-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-L-tyrosyl-N^5-carbamoyl-D-ornithyl-L-leucyl-L-arginyl-L-prolyl-D-alaninamide $C_{70}H_{92}ClN_{17}O_{14}$ *antineoplastic* 
colfoscerili palmitas colfosceril palmitate	choline hydroxide, dihydrogen phosphate, inner salt, ester with L-1,2-dipalmitin *or* 1,2-dipalmitoyl-*sn*-glycero-3-phosphocholine $C_{40}H_{80}NO_8P$ 63-89-8 *surfactant replacement* 
corticorelinum corticorelin	corticotropin-releasing factor The source of the material should be indicated. $C_{205}H_{339}N_{59}O_{63}S$ *diagnostic agent* 

Proposed International Nonproprietary Name (Latin, English)	*Chemical Name or Description, Molecular and Graphic Formulae Chemical Abstracts Service (CAS) registry number Action and use*
crospovidonum crospovidone	1-vinyl-2-pyrrolidinone polymer, crosslinked $(C_6H_9NO)n$ 9003-39-8 *pharmaceutical aid*
	
dalfopristinum dalfopristin	(3*R*,4*R*,5*E*,10*E*,12*E*,14*S*,26*R*,26a*S*)-26-[[2-(diethylamino)ethyl]sulfonyl]-8,9,14,15,24,25,26,26a-octahydro-14-hydroxy-3-isopropyl-4,12-dimethyl-3*H*-21,18-nitrilo-1*H*,22*H*-pyrrolo[2,1*c*][1,8,4,19]dioxadiazacyclotetracosine-1,7,16,22(4*H*,7*H*)-tetrone $C_{34}H_{50}N_4O_9S$ 112362-50-2 *antibacterial*
	
dalteparinum natricum dalteparin sodium	Sodium salt of depolymerized heparin obtained by nitrous acid degradation of heparin from pork intestinal mucosa, the majority of the components have a 2-*O*-sulfo-α-L-idopyranosuronic acid structure at the non-reducing end and a 6-*O*-sulfo-2,5-anhydro-D-mannitol structure at the reducing end of their chain; the average relative molecular mass is about 5000, 90 per cent of which ranging between 2000 and 9000; the degree of sulfatation is 2 to 2,5 per disaccharidic unit. *anticoagulant*
dalvastatinum dalvastatin	(±)-(4*R**,6*S**)-6-[(*E*)-2-[2-(4-fluoro-*m*-tolyl)-4,4,6,6-tetramethyl-1-cyclohexen-1-yl]vinyl]tetrahydro-4-hydroxy-2*H*-pyran-2-one $C_{24}H_{31}FO_3$ 132100-55-1 *antihyperlipidaemic*
	
dexormaplatinum dexormaplatin	(+)-*trans*-tetrachloro(1,2-cyclohexanediamine)platinum $C_6H_{14}Cl_4N_2Pt$ 96392-96-0 *antineoplastic*
	

Proposed International Nonproprietary Name (Latin, English)	*Chemical Name or Description, Molecular and Graphic Formulae* *Chemical Abstracts Service (CAS) registry number* *Action and use*
didanosinum didanosine	2′,3′-dideoxyinosine $C_{10}H_{12}N_4O_3$ 69655-05-6 *antiviral*



diethyltoluamidum diethyltoluamide	*N,N*-diethyl-*m*-toluamide $C_{12}H_{17}NO$ 134-62-3 *insect repellent*



dofetilidum dofetilide	*β*-[(*p*-methanesulfonamidophenethyl)methylamino]methanesulfono-*p*-phenetidide $C_{19}H_{27}N_3O_5S_2$ 115256-11-6 *antidysrhythmic*



draflazinum draflazine	(±)-4′-amino-4-[5,5-bis(*p*-fluorophenyl)pentyl]-2-carbamoyl-2′,6′-dichloro-1-piperazineacetanilide $C_{30}H_{33}Cl_2F_2N_5O_2$ 120770-34-5 *coronary vasodilator*



eberconazolum eberconazole	(±)-1-(2,4-dichloro-10,11-dihydro-5*H*-dibenzo[*a,d*]cyclohepten-5-yl)imidazole $C_{18}H_{14}Cl_2N_2$ 126326-82-9 *antifungal*



Proposed International Nonproprietary Name (Latin, English)	*Chemical Name or Description, Molecular and Graphic Formulae* *Chemical Abstracts Service (CAS) registry number* *Action and use*
ecabetum ecabet	13-isopropyl-12-sulfopodocarpa-8,11,13-trien-15-oic acid $C_{20}H_{28}O_5S$ 33159-27-2 *antiulcer*
	
englitazonum englitazone	(–)-5-[[(2*R*)-2-benzyl-6-chromanyl]methyl]-2,4-thiazolidinedione $C_{20}H_{19}NO_3S$ 109229-58-5 *antidiabetic*
	
enloplatinum enloplatin	*cis*-(1,1-cyclobutanedicarboxylato)[tetrahydro-4*H*-pyran-4,4-bis(methylamine)]platinum $C_{13}H_{22}N_2O_5Pt$ 111523-41-2 *antineoplastic*
	
eprobemidum eprobemide	*p*-chloro-*N*-(3-morpholinopropyl)benzamide $C_{14}H_{19}ClN_2O_2$ 87940-60-1 *antidepressant*
	
etarotenum etarotene	6-[(*E*)-*p*-(ethylsulfonyl)-α-methylstyryl]-1,2,3,4-tetrahydro-1,1,4,4-tetramethylnaphthalene $C_{25}H_{32}O_2S$ 87719-32-2 *dermatological*
	

Proposed International Nonproprietary Name (Latin, English)	*Chemical Name or Description, Molecular and Graphic Formulae* *Chemical Abstracts Service (CAS) registry number* *Action and use*
fadrozolum fadrozole	(±)-*p*-(5,6,7,8-tetrahydroimidazo[1,5-*a*]pyridin-5-yl)benzonitrile $C_{14}H_{13}N_3$ 102676-47-1 *antineoplastic*
	
fantofaronum fantofarone	1-[[*p*-[3-[(3,4-dimethoxyphenethyl)methylamino]propoxy]phenyl]-sulfonyl]-2-isopropylindolizine $C_{33}H_{38}N_2O_5S$ 114432-13-2 *calcium antagonist*
	
fasudilum fasudil	hexahydro-1-(5-isoquinolylsulfonyl)-1*H*-1,4-diazepine $C_{14}H_{17}N_3O_2S$ 103745-39-7 *vasodilator*
	
filgrastimum filgrastim	*N*-L-methionylcolony-stimulating factor (human clone 1034) $C_{845}H_{1339}N_{223}O_{243}S_9$ 121181-53-1 *immunomodulator*
flosatidilum flosatidil	isobutyl [2-(dimethylamino)ethyl][[[*o*-(methylthio)phenyl]-[*m*-(trifluoromethyl)benzyl]carbamoyl]methyl]carbamate $C_{25}H_{34}F_3N_3O_3S$ 113593-34-3 *calcium antagonist*
	
fluorodopum (^{18}F) fluorodopa (^{18}F)	3-(2-fluoro-^{18}*F*-4,5-dihydroxyphenyl)-L-alanine $C_9H_{10}{}^{18}FNO_4$ 92812-82-3 *radioactive diagnostic agent*
	

Proposed International Nonproprietary Name (Latin, English)	*Chemical Name or Description, Molecular and Graphic Formulae* *Chemical Abstracts Service (CAS) registry number* *Action and use*
gadoteridolum gadoteridol	(±)-[10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclodecane-1,4,7-triacetato[(3-)]gadolinium $C_{17}H_{29}GdN_4O_7$ 120066-54-8 *paramagnetic contrast medium*
	
irinotecanum irinotecan	(+)-7-ethyl-10-hydroxycamptothecine 10-[1,4′-biperidine]-1′-carboxylate *or* (+)-(*S*)-4,11-diethyl-4,9-dihydroxy-1*H*-pyrano[3′,4′:6,7]indolizino[1,2-*b*]-quinoline-3,14(4*H*,12*H*)-dione 9-[1,4′-bipiperidine]-1′-carboxylate $C_{33}H_{38}N_4O_6$ 97682-44-5 *antineoplastic*
	
lanreotidum lanreotide	3-(2-naphthyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-L-threoninamide, cyclic (2→7)-disulfide $C_{54}H_{69}N_{11}O_{10}S_2$ 108736-35-2 *antineoplastic*
	
lenograstimum lenograstim	133-[*O*-[*O*-(*N*-acetyl-α-neuraminosyl)-(2→3)-[*O*-β-D-galactopyranosyl-(1→3)]-2-acetamido-2-deoxy-β-D-galactopyranosyl]-L-threonine]colony-stimulating factor (human clone 1034) mixture with 133-[*O*-[*O*-(*N*-acetyl-α-neuraminosyl)-(2→6)-*O*-[*O*-(*N*-acetyl-α-neuraminosyl)-(2→3)-β-D-galactopyranosyl-(1→3)]-2-acetamido-2-deoxy-β-D-galactopyranosyl]-L-threonine]colony-stimulating factor (human clone 1034) *immunomodulator*

Proposed International Nonproprietary Name (Latin, English)	*Chemical Name or Description, Molecular and Graphic Formulae* *Chemical Abstracts Service (CAS) registry number* *Action and use*
leuciglumerum leuciglumer	L-leucine polymer with 5-methyl hydrogen L-glutamate $(C_6H_{13}NO_2)m \cdot (C_6H_{11}NO_4)n$ 41385-14-2 *dermatological*



[illegible]rubicinum leurubicin	(8*S*,10*S*)-10-[[3-[(*S*)-2-amino-4-methylvaleramido]-2,3,6-trideoxy-α-L-*lyxo*-hexopyranosyl]oxy]-8-glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione $C_{33}H_{40}N_2O_{12}$ 70774-25-3 *antineoplastic*



levofloxacinum [illegible]ofloxacin	(–)-(*S*)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7*H*-pyrido[1,2,3-*de*]-1,4-benzoxazine-6-carboxylic acid $C_{18}H_{20}FN_3O_4$ 100986-85-4 *antibacterial*



levomentholum levomenthol	(–)-(1*R*,3*R*,4*S*)-menthol $C_{10}H_{20}O$ 2216-51-5 *decongestant, carminative*



Proposed International Nonproprietary Name (Latin, English)	*Chemical Name or Description, Molecular and Graphic Formulae* *Chemical Abstracts Service (CAS) registry number* *Action and use*
liarozolum liarozole	(±)-5-(*m*-chloro-α-imidazol-1-ylbenzyl)benzimidazole $C_{17}H_{13}ClN_4$ 115575-11-6 *antiandrogen* 
liranaftatum liranaftate	*O*-(5,6,7,8,-tetrahydro-2-naphthyl) 6-methoxy-*N*-methylthio-2-pyridinecarbamate $C_{18}H_{20}N_2O_2S$ 88678-31-3 *antifungal* 
litoxetinum litoxetine	4-(2-naphthylmethoxy)piperidine $C_{16}H_{19}NO$ 86811-09-8 *antidepressant* 
loteprednolum loteprednol	chloromethyl 11β,17-dihydroxy-3-oxoandrosta-1.4-diene-17β-carboxylic acid $C_{21}H_{26}ClO_5$ 129260-79-3 *anti-inflammatory* 
loxoribinum loxoribine	7-allyl-2-amino-9-β-D-ribofuranosylpurine-6,8(1*H*,9*H*)-dione $C_{13}H_{17}N_5O_6$ 121288-39-9 *immunostimulant* 

Proposed International Nonproprietary Name (Latin, English)	*Chemical Name or Description, Molecular and Graphic Formulae* *Chemical Abstracts Service (CAS) registry number* *Action and use*
lufironilum lufironil	*N,N'*-bis(2-methoxyethyl)-2,4-pyridinedicarboxamide $C_{13}H_{19}N_3O_4$ 128075-79-6 *collagen inhibitor* 
ibuprofenum ibuprofen	(±)-*N*-(2-hydroxyethyl)-*p*-isobutylhydratropamide $C_{15}H_{23}NO_2$ 82821-47-4 *analgesic, non-steroidal anti-inflammatory* 
melarsominum melarsomine	bis(2-aminoethyl) *p*-[(4,6-diamino-*s*-triazin-2-yl)amino]dithiobenzenearsonite $C_{13}H_{21}AsN_8S_2$ 128470-15-5 *antifilarial* 
minamestanum minamestane	4-aminoandrosta-1,4,6-triene-3,17-dione $C_{19}H_{23}NO_2$ 105051-87-4 *antineoplastic* 
mipragosidum mipragoside	*N*-(II^3-*N*-acetylneuraminosylgangliotetraosyl)ceramide, isopropyl ester $C_{76}H_{137}N_3O_{31}$ 131129-98-1 *ganglioside* 

Proposed International Nonproprietary Name (Latin, English)	*Chemical Name or Description, Molecular and Graphic Formulae* *Chemical Abstracts Service (CAS) registry number* *Action and use*
mirfentanilum mirfentanil	*N*-(1-phenethyl-4-piperidyl)-*N*-pyrazinyl-2-furamide $C_{22}H_{24}N_4O_2$ 117523-47-4 *analgesic* 
mizolastinum mizolastine	2-[[1-[1-(*p*-fluorobenzyl)-2-benzimidazolyl]-4-piperidyl]methylamino]-4(3*H*)-pyrimidinone $C_{24}H_{25}FN_6O$ 108612-45-9 *antihistaminic* 
mofezolacum mofezolac	3,4-bis(*p*-methoxyphenyl)-5-isoxazoleacetic acid $C_{19}H_{17}NO_5$ 78967-07-4 *analgesic, non-steroidal anti-inflammatory* 
molgramostimum molgramostim	colony-stimulating factor 2 (human clone pHG_{25} protein moiety reduced) $C_{639}H_{1007}N_{171}O_{196}S_8$ (for protein moiety) 99283-10-0 *immunomodulator*
mosapraminum mosapramine	(±)-1′-[3-(3-chloro-10,11-dihydro-5*H*-dibenz[*b*,*f*]azepin-5-yl)propyl]hexahydrospiro[imidazo[1,2-*a*]pyridine-3(2*H*),4′-piperidin]-2-one $C_{28}H_{35}ClN_4O$ 89419-40-9 *neuroleptic* 

Proposed International Nonproprietary Name (Latin, English)	*Chemical Name or Description, Molecular and Graphic Formulae* *Chemical Abstracts Service (CAS) registry number* *Action and use*
nadifloxacinum nadifloxacin	(±)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidino)-5-methyl-1-oxo-1*H*,5*H*-benzo[*ij*]quinolizine-2-carboxylic acid $C_{19}H_{21}FN_2O_4$ 124858-35-1 *antibacterial* 
~~dro~~parinum calcium ~~dro~~parin calcium	Calcium salt of depolymerized heparin obtained by nitrous acid degradation of heparin from pork intestinal mucosa; the majority of the components have a 2-*O*-sulfo-α-L-idopyranosuronic acid structure at the non-reducing end and a 6-*O*-sulfo-2,5-anhydro-D-mannitol structure at the reducing end of their chain; the average relative molecular mass is 4000 to 5000; the degree of sulfatation is about 2,1 per disaccharidic unit. *anticoagulant*
nafagrelum nafagrel	(±)-5,6,7,8-tetrahydro-6-(imidazol-1-ylmethyl)-2-naphthoic acid $C_{15}H_{16}N_2O_2$ 97901-21-8 *thromboxane A_2 synthetase inhibitor* 
nefiracetamum nefiracetam	2-oxo-1-pyrrolidineaceto-2′,6′-xylidide $C_{14}H_{18}N_2O_2$ 77191-36-7 *nootropic agent* 
nestifyllinum nestifylline	7-(1,3-dithiolan-2-ylmethyl)theophylline $C_{11}H_{14}N_4O_2S_2$ 116763-36-1 *antiasthmatic* 
ocaperidonum ocaperidone	3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidino]ethyl]-2,9-dimethyl-4*H*-pyrido[1,2-*a*]pyrimidin-4-one $C_{24}H_{25}FN_4O_2$ 129029-23-8 *antipsychotic* 

Proposed International Nonproprietary Name (Latin, English)	*Chemical Name or Description, Molecular and Graphic Formulae* *Chemical Abstracts Service (CAS) registry number* *Action and use*
oxiglutationum oxiglutatione	*N,N'*-[dithiobis[(*R*)-1-[(carboxymethyl)carbamoyl]ethylene]]di-L-glutamine $C_{20}H_{32}N_6O_{12}S_2$ 27025-41-8 
palonidipinum palonidipine	(±)-3-(benzylmethylamino)-2,2-dimethylpropyl methyl 4-(2-fluoro-5-nitrophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate $C_{29}H_{34}FN_3O_6$ 96515-73-0 *calcium antagonist* 
panipenemum panipenem	(+)-(5*R*,6*S*)-3-[[(*S*)-1-acetimidoyl-3-pyrrolidinyl]thio]-6-[(*R*)-1-hydroxyethyl]-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid $C_{15}H_{21}N_3O_4S$ 87726-17-8 *antibiotic* 
parnaparinum natrium parnaparin sodium	Sodium salt of depolymerized heparin obtained by hydrogen peroxide and cupric acetate degradation of heparin from pork intestinal mucosa; the majority of the components have a 2-*O*-sulfo-α-L-idopyranosuronic acid structure at the non-reducing end and a 2-*N*,6-*O*-disulfo-D-glucosamine structure at the reducing end of their chain; the average relative molecular mass is between 4000 and 6000 (5000 ± 10 per cent), the degree of sulfatation is 2,15 (± 10 per cent) per disaccharidic unit. *anticoagulant*
pegaspargasum pegaspargase	asparaginase, reaction product with succinic anhydride, esters with polyethylene glycol monomethyl ether 130167-69-0 *antineoplastic* 

Proposed International Nonproprietary Name (Latin, English)	*Chemical Name or Description, Molecular and Graphic Formulae* *Chemical Abstracts Service (CAS) registry number* *Action and use*
picumeterolum picumeterol	(–)-(*R*)-4-amino-3,5-dichloro-α-[[[6-[2-(2-pyridyl)ethoxy]hexyl]amino]-methyl]benzyl alcohol $C_{21}H_{29}Cl_2N_3O_2$ 130641-36-0 *β_2-adrenoreceptor agonist* 
pirodomastum pirodomast	4-hydroxy-1-phenyl-3-(1-pyrrolidinyl)-1,8-naphthyridin-2(1*H*)-one $C_{18}H_{17}N_3O_2$ 108310-20-9 *antiallergic* 
porfimerum natricum porfimer sodium	photofrin II 87806-31-3 *photosensitizing agent* 
prinoxodanum prinoxodan	3,4-dihydro-3-methyl-6-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-2(1*H*)-quinazolinone $C_{13}H_{14}N_4O_2$ 111786-07-3 *cardiac stimulant* 

Proposed International Nonproprietary Name (Latin, English)	*Chemical Name or Description, Molecular and Graphic Formulae* *Chemical Abstracts Service (CAS) registry number* *Action and use*
quinotolastum quinotolast	4-oxo-1-phenoxy-*N*-1*H*-tetrazol-5-yl-4*H*-quinolizine-3-carboxamide $C_{17}H_{12}N_6O_3$ 101193-40-2 *antiallergic*
	
quinupristinum quinupristin	*N*-[(6*R*,9*S*,10*R*,13*S*,15a*S*,22*S*,24a*S*)-22-[*p*-(dimethylamino)benzyl]-6-ethyldocosahydro-10,23-dimethyl-5,8,12,15,17,21,24-heptaoxo-13-phenyl-18-[[(3*S*)-3-quinuclidinylthio]methyl]-12*H*-pyrido[2,1-*l*][1,4,7,10,13,16]oxapentaazacyclononadecin-9-yl]-3-hydroxy picolinamide $C_{53}H_{67}N_9O_{10}S$ 120138-50-3 *antibacterial*
	
racementholum racementhol	(±)-(1*R**,3*R**,4*S**)-menthol $C_{10}H_{20}O$ 15356-70-4 *decongestant, carminative*
	
regramostimum regramostim	colony-stimulating factor 2 (human clone pCSF-1 protein moiety reduced), glycoform GMC 89-107 $C_{637}H_{1003}N_{171}O_{197}S_5$ 127757-91-9 *immunomodulator*
reviparinum natrium reviparin sodium	Sodium salt of depolymerized heparin obtained by nitrous acid degradation of heparin from pork intestinal mucosa; the majority of the components have a 2-*O*-sulfo-α-L-idopyranosuronic acid structure at the non-reducing end and a 6-*O*-sulfo-2,5-anhydro-D-mannitol structure at the reducing end of their chain; the average relative molecular mass is 3500 to 4500, 90 per cent of which ranging between 2000 and 8000; the degree of sulfatation is about 2,2 per disaccharidic unit. *anticoagulant*

Proposed International Nonproprietary Name (Latin, English)	*Chemical Name or Description, Molecular and Graphic Formulae* *Chemical Abstracts Service (CAS) registry number* *Action and use*
ritolukastum ritolukast	1,1,1-trifluoro-α-2-quinolylmethanesulfon-*m*-anisidide $C_{17}H_{13}F_3N_2O_3S$ 111974-60-8 *antiasthmatic*



sagandipinum sagandipine	methyl (5-piperidinomethyl)furfuryl 4-(*o*-fluorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate $C_{27}H_{31}FN_2O_5$ 126294-30-2 *calcium antagonist*



semotiadilum semotiadil	(+)-(*R*)-2-[5-methoxy-2-[3-[methyl[2-[3,4-(methylenedioxy)phenoxy]ethyl]-amino]propoxy]phenyl]-4-methyl-2*H*-1,4-benzothiazin-3(4*H*)-one $C_{29}H_{32}N_2O_6S$ 116476-13-2 *calcium antagonist*



sorivudinum sorivudine	(+)-1-β-D-arabinofuranosyl-5-[(*E*)-2-bromovinyl]uracil $C_{11}H_{13}BrN_2O_6$ 77181-69-2 *antiviral*



Proposed International Nonproprietary Name (Latin, English)	*Chemical Name or Description, Molecular and Graphic Formulae* *Chemical Abstracts Service (CAS) registry number* *Action and use*
sumarotenum sumarotene	1,2,3,4-tetrahydro-1,1,4,4-tetramethyl-6-[(*E*)-α-methyl-*p*-(methylsulfonyl)-styryl]naphthalene $C_{24}H_{30}O_2S$ 105687-93-2 *dermatological* 
suplatastum tosilas suplatast tosilate	(±)-[2-[[*p*-(3-ethoxy-2-hydroxypropoxy)phenyl]carbamoyl]ethyl]-dimethylsulfonium *p*-toluenesulfonate $C_{23}H_{33}NO_7S_2$ 94055-76-2 *anti-asthmatic, antiallergic* 
tamsulosinum tamsulosin	(−)-(*R*)-5-[2-[[2-(*o*-ethoxyphenoxy)ethyl]amino]propyl]-2-methoxybenzenesulfonamide $C_{20}H_{28}N_2O_5S$ 106133-20-4 *α_1-adrenoreceptor antagonist* 
technetii (^{99m}Tc) bicisas technetium (^{99m}Tc) bicisate	[*N,N'*-ethylenedi-L-cysteinato(3-)]oxo[^{99m}Tc] technetium(V), diethyl ester $C_{12}H_{21}N_2O_5S_2{}^{99m}Tc$ 121281-41-2 *radiocontrast medium* 
tematropii metilsulfas tematropium metilsulfate	3α-hydroxy-8-methyl-1α*H*,5α*H*-tropanium methyl sulfate (salt), (±)-ethyl hydrogen phenylmalonate $C_{21}H_{31}NO_8S$ 113932-41-5 *anticholinergic* 

Proposed International Nonproprietary Name (Latin, English)	*Chemical Name or Description, Molecular and Graphic Formulae* *Chemical Abstracts Service (CAS) registry number* *Action and use*
temocaprilum temocapril	(+)-(2*S*,6*R*)-6-[[(1*S*)-1-carboxy-3-phenylpropyl]amino]tetrahydro-5-oxo-2-(2-thienyl)-1,4-thiazepine-4(5*H*)-acetic acid, 6-ethyl ester $C_{23}H_{28}N_2O_5S_2$ 111902-57-9 *angiotensin-converting enzyme inhibitor*
	
terikalantum terikalant	(–)-1-[2-(4-chromanyl)ethyl]-4-(3,4-dimethoxyphenyl)piperidine $C_{24}H_{31}NO_3$ *potassic channel blocker*
	
tibeglisenum tibeglisene	(±)-5-(*p*-chlorophenyl)-2-(*p*-tolylsulfonyl)-4-pentynoic acid $C_{18}H_{15}ClO_4S$ 129731-11-9 *antidiabetic*
	
tulopafantum tulopafant	(+)-3′-benzoyl-3-(3-pyridyl)-1*H*,3*H*-pyrrolo[1,2-*c*]thiazole-7-carboxanilide $C_{25}H_{19}N_3O_2S$ 116289-53-3 *platelet-activating factor antagonist*
	
vamicamidum vamicamide	(±)-(*R**)-α-[(*R**)-2-(dimethylamino)propyl]-α-phenyl-2-pyridineacetamide $C_{18}H_{23}N_3O$ 132373-81-0 *anticholinergic, spasmolytic*
	

Proposed International Nonproprietary Name (Latin, English)	*Chemical Name or Description, Molecular and Graphic Formulae* *Chemical Abstracts Service (CAS) registry number* *Action and use*
vinfosiltinum vinfosiltine	[23(*S*)]-4-deacetyl-3-de(methoxycarbonyl)-3-[(2-methyl-1-phosphonopropyl)carbamoyl]vincaleukoblastine, diethyl ester $C_{51}H_{72}N_5O_{10}P$ 123286-00-0 *antineoplastic*
	
vinleucinolum vinleucinol	[23(1*S*,2*S*)]-4-deacetyl-3-[(1-carboxy-2-methylbutyl)carbamoyl]-3-(demethoxycarbonyl)vincaleukoblastine, ethyl ester $C_{57}H_{69}N_5O_8$ *antineoplastic*
	
vorozolum vorozole	(+)-6-(*p*-chloro-α-1*H*-1,2,4-triazol-1-ylbenzyl)-1-methyl-1*H*-benzotriazole $C_{16}H_{13}ClN_6$ 129731-10-8 *antineoplastic*
	
zabiciprilatum zabiciprilat	(*S*)-2-[(*S*)-*N*-[(*S*)-1-carboxy-3-phenylpropyl]alanyl]-2-azabicyclo[2.2.2]octane-3-carboxylic acid $C_{21}H_{28}N_2O_5$ 90103-92-7 *antihypertensive*
	

Proposed International Nonproprietary Name (Latin, English)	*Chemical Name or Description, Molecular and Graphic Formulae* *Chemical Abstracts Service (CAS) registry number* *Action and use*
zalospironum zalospirone	(1*R**,2*R**,5*S**,6*S**,7*S**,8*R**)-*N*-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-tricyclo[4 2 2.O^{2,5}]deca-3,9-diene-7,8-dicarboximide $C_{24}H_{29}N_5O_2$ 114298-18-9 *anxiolytic*
	
~~zaltoprofenum~~ ~~zaltoprofen~~	(±)-10,11-dihydro-α-methyl-10-oxodibenzo[*b,f*]thiepin-2-acetic acid $C_{17}H_{14}O_3S$ 89482-00-8 *analgesic, nonsteroidal anti-inflammatory*
	
zatosetronum zatosetron	5-chloro-2,3-dihydro-2,2-dimethyl-*N*-1α*H*,5α*H*-tropan-3α-yl-7-benzofurancarboxamide $C_{19}H_{25}ClN_2O_2$ 123482-22-4 *antimigraine*
	
zenarestatum zenarestat	3-(4-bromo-2-fluorobenzyl)-7-chloro-3,4-dihydro-2,4-dioxo-1(2*H*)-quinazolineacetic acid $C_{17}H_{11}BrClFN_2O_4$ 112733-06-9 *aldose reductase inhibitor*
	
zopolrestatum zopolrestat	3,4-dihydro-4-oxo-3-[[5-(trifluoromethyl)-2-benzothiazolyl]methyl]-1-phthalazineacetic acid $C_{19}H_{12}F_3N_3O_3S$ 110703-94-1 *aldose reductase inhibitor*
	

Names for Radicals and Groups

Some substances for which a proposed international nonproprietary name has been established may be used in the form of salts or esters. The radicals or groups involved may be of complex composition and it is then inconvenient to refer to them in systematic chemical nomenclature. Consequently, shorter nonproprietary names for some radicals and groups have been devised or selected, and they are suggested for use with the proposed international nonproprietary names.

acistras
acistrate

2'-acetate, stearate (salt)
$C_{20}H_{38}O_4$



etabonas
etabonate

ethyl carbonate
$C_3H_5O_3$



pivetilum
pivetil

1-hydroxyethyl pivalate (ester)
$C_7H_{13}O_3$



triflutas
triflutate

trifluoroacetate
$C_2HF_3O_2$



AMENDMENTS

Chronicle of the World Health Organization, Vol. 7, No. 10, 1953

Proposed International Nonproprietary Names (Prop. INN): List 1

p. 118	polyvidonum polyvidone	*replace the chemical name by the following* 1-vinyl-2-pyrrolidinone polymer, linear

WHO Chronicle, Vol. 24, No. 9, 1970

Proposed International Nonproprietary Names (Prop. INN): List 24

p. 433	fendizoatum fendizoate	*replace the chemical name, the CAS registry number andt the graphic formula by the following:* 2-[(6-hydroxybiphenyl-3-yl)carbonyl]benzoate 84627-04-3



Supplement to WHO Chronicle, Vol. 34, No. 9, 1980

Proposed International Nonproprietary Names (Prop. INN): List 44

p. 5	loprazolamum loprazolam	*replace the chemical name and the CAS registry number by the following:* (*Z*)-6-(*o*-chlorophenyl)-2,4-dihydro-2-[(4-methyl-1-piperazinyl)methylene]-8-nitro-1*H*-imidazo[1,2-*a*][1,4]benzodiazepin-1-one 70111-54-5

Supplement to WHO Chronicle, Vol. 38, No. 4, 1984

Proposed International Nonproprietary Names (Prop. INN): List 52

p. 9	enoxaparinum enoxaparin	*delete the whole entry*
	insert enoxaparinum natrium enoxaparin sodium	*insert* Sodium salt of depolymerized heparin obtained by alcaline degradation of heparin benzyl ester from pork intestinal mucosa; the majority of the components present a 2-*O*-sulfo-4-enepyranosuronic acid structure at the non-reducing end and a 2-*N*,6-*O*-disulfo-D-glucosamine structure at the reducing end of their chain; the average relative molecular mass is about 4500, ranging between 3500 and 5500, the degree of sulfatation is about 2 per disaccharidic unit. anticoagulant

Proposed International Nonproprietary Names (Prop. INN): List 55

p. 17 efrotomycinum
efrotomycin

replace the chemical name, and the graphic formula by the following:

an antibiotic produced by *Streptomyces lactamdurans*
efrotomycin A_1 *or*
(*αS,2R,3R,4R,6S*)-4-[[6-deoxy-4-*O*-(6-deoxy-2,4-di-*O*-methyl-*α*-L-manno-pyranosyl)-3-*O*-methyl-*β*-D-allopyranosyl]oxy]-*N*-[(2*E*,4*E*,6*S*,7*R*)-7-[(2*S*,3*S*,-4*R*,5*R*)-5-[(1*E*,3*E*,5*E*)-6-(1,2-dihydro-4-hydroxy-1-methyl-2-oxonicotinoyl)-1,3,5-heptatrienyl]tetrahydro-3,4-dihydroxy-2-furyl]-6-methoxy-5-methyl-2,4-octadienyl]-*α*-ethyltetrahydro-2,3-dihydroxy-5,5-dimethyl-6-[(1*E*,3*Z*)-1,3-pentadienyl]-2*H*-pyran-2-acetamide



WHO Drug Information, Vol. 1, No. 3, 1987

Proposed International Nonproprietary Names (Prop. INN): List 58

p. 182	*delete*	*insert*
	levdropropizinum levdropropizine	levodropropizinum levodropropizine

WHO Drug Information, Vol. 2, No. 4, 1988

Proposed International Nonproprietary Names (Prop. INN): List 60

p. 2 acemannanum
acemannan

delete the graphic formula and replace the description by the following:

Acemannan is a highly acetylated, polydispersed, linear mannan obtained from the mucilage of *Aloe barbadensis*, Miller (aloe vera).

WHO Drug Information, Vol. 3, No. 2, 1989

Proposed International Nonproprietary Names (Prop. INN): List 61

p. 14 moxidectinum
moxidectin

replace the chemical name by the following:

(6*R*,25*S*)-5-*O*-demethyl-28-deoxy-25-[(*E*)-1,3-dimethyl-1-butenyl]-6,28-epoxy-23-oxomilbemycin B 23-(*E*)-(*O*-methyloxime)

p. 17	*delete*	*insert*
	taludipinum taludipine	teludipinum teludipine

Proposed International Nonproprietary Names (Prop. INN): List 62

p. 8 fosquidonum
fosquidone

replace the chemical name by the following:

benzyl (±)-5,8,13,14-tetrahydro-14-methyl-8,13-dioxobenz[5,6]isoindolo-[2,1-*b*]isoquinolin-9-yl hydrogen phosphate

Proposed International Nonproprietary Names (Prop. INN): List 63

p. 5 doramectinum
doramectin

replace the chemical name by the following:

25-cyclohexyl-5-*O*-demethyl-25-de(1-methylpropyl)avermectin A_{1a} *or* (2a*E*,4*E*,8*E*)-5′*S*,6*S*,6′*R*,7*S*,11*R*,13*S*,15*S*,17a*R*,20*R*,20a*R*,20b*S*)-6′-cyclohexyl-5′,6,6′,7,10,11,14,15,17a,20,20a,20b-dodecahydro-20,20b-dihydroxy-5′,6,8,19-tetramethyl-17-oxospiro[11,15-methano-2*H*,13*H*,17*H*-furo-[4,3,2-*pq*][2,6]benzodioxacyclooctadecin-13,2′-[2*H*]pyran]-7-yl 2,6-dideoxy-4-*O*-(2,6-dideoxy-3-*O*-methyl-α-L-*arabino*-hexopyranosyl)-3-*O*-methyl-α-L-*arabino*-hexopyranoside

p. 6 giracodazolum
giracodazole

replace the chemical name by the following:

(α*S*)-2-amino-α-[(1*S*)-2-amino-1-chloroethyl]imidazole-4-methanol

p. 8 nemazolinum
nemazoline

insert the following CAS registry number.

130759-56-7

neticonazolum
neticonazole

replace the CAS registry number by the following:

130726-68-0

p. 14 tenosiprolum
tenosiprol

insert the following CAS registry number.

129336-81-8

p. 16 zilascorbum (²H)
zilascorb (²H)

replace the chemical name by the following:

5,6-*O*-[(*RS*)-benzylidene-α-*d*]-L-ascorbic acid

Procedure and Guiding Principles

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances and General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will from now on be reproduced in uneven numbers of proposed INN lists only.